Contemporary Management of Familial and Multifactorial Chylomicronemia Syndromes in Italy: Insights From the National LIPIGEN Registry
Authors:
- Laura D'ERasmoLDLaura D'ERasmo
- Daniele TramontanoDTDaniele Tramontano
- Alessia Di CostanzoACAlessia Di Costanzo
- Manuela CasulaMCManuela Casula
- Federica GalimbertiFGFederica Galimberti
- Francesco BarattaFBFrancesco Baratta
- Angelo Baldassare CefalùAngelo Baldassare Cefalù
- Patrizia TarugiPTPatrizia Tarugi
- Sebastiano CalandraSCSebastiano Calandra
- Alberto ZambonAZAlberto Zambon
- Maurizio AvernaMAMaurizio Averna
- Alberico Luigi CatapanoAlberico Luigi Catapano
Open Access
- 1 December 2025
- journal article
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 45 (12) , 2264-2276
Abstract
BACKGROUND: We aimed to compare the molecular and clinical characteristics of patients identified in Italy as affected by either familial chylomicronemia syndrome (FCS) or multifactorial chylomicronemia syndrome (MCS) and to assess the overall benefit of novel triglyceride-lowering therapies prescribed to these patients within the routine clinical care. METHODS: From the national LIPIGEN-sHTG (Lipid Transport Disorders Italian Genetic Network—Severe Hypertriglyceridemia) registry, 169 patients (57 FCS, 51 MCS, 61 variant-negative, variant-negative MCS) were retrospectively analyzed. Data on clinical and genetic characteristics, medical history, and medications were collected. Peak triglyceride levels were used to define untreated lipid phenotypes. RESULTS: In FCS, 72% exhibited biallelic LPL and 28% non-LPL variants; in MCS, 38% (n=19) carried LPL variants, and 38% (n=19) carried APOA5 variants, whereas the remaining individuals were carriers of LMF1 (n=3), GPIHBP1 (n=2), and CREB3L3 or GPD1 variants (n=8), respectively. Peak TGs were highest in FCS (3000 mg/dL [interquartile range, 2116.0–4265.0]), followed by MCS (1817 mg/dL [interquartile range, 1370.0–3062.0]) and variant-negative MCS (1340.0 mg/dL [interquartile range, 946.5–2508.5]; P LPL variants. Lomitapide and volanesorsen provide better triglyceride control, yet only one-third of FCS were treated with these drugs in the routine clinical practice.Keywords
This publication has 37 references indexed in Scilit:
- The vicious circle of chronic kidney disease and hypertriglyceridemia: What is first, the hen or the egg?Atherosclerosis, 2025
- Long-term effects of volanesorsen on triglycerides and pancreatitis in patients with familial chylomicronaemia syndrome (FCS) in the UK Early Access to Medicines Scheme (EAMS)Atherosclerosis, 2023
- Efficacy and safety of lomitapide in familial chylomicronaemia syndromeAtherosclerosis, 2022
- Rare Treatments for Rare Dyslipidemias: New Perspectives in the Treatment of Homozygous Familial Hypercholesterolemia (HoFH) and Familial Chylomicronemia Syndrome (FCS)Current Atherosclerosis Reports, 2021
- Effectiveness and safety of lomitapide in a patient with familial chylomicronemia syndromeEndocrine, 2020
- Familial Chylomicronemia Syndrome (FCS): Recent Data on Diagnosis and TreatmentCurrent Atherosclerosis Reports, 2020
- Chylomicronemia: Differences between familial chylomicronemia syndrome and multifactorial chylomicronemiaAtherosclerosis, 2019
- Clinical and biochemical features of different molecular etiologies of familial chylomicronemiaJournal of Clinical Lipidology, 2018
- Familial hypercholesterolemia: The Italian Atherosclerosis Society Network (LIPIGEN)Atherosclerosis Supplements, 2017
- Spectrum of mutations of the LPL gene identified in Italy in patients with severe hypertriglyceridemiaAtherosclerosis, 2015